In the high-stakes environment of drug development, Chemistry, Manufacturing, and Controls (CMC) is too often viewed as a regulatory hurdle to clear rather than a core strategic function. This misperception has led to costly delays, clinical holds, and even outright refusals to file. In this white paper, we explore how the “CMC trap” continues to derail promising therapies and outline how organizations can shift their mindset to integrate CMC thinking early and intentionally.
White Paper
The CMC Trap: How Chemistry, Manufacturing, and Controls Failures Derail Drug Development
Download PDF
Related Resources
All Resources

post
Oral Drug Product Development of Small Molecules
Read More

white-paper
The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China
Read More

post
Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in
Read More

white-paper
Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?
Read More
Let's move from science to success.
Let’s Talk
